12 reports

The prevalence rate for FH ranges between one in ## to one in ## people.

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Clinical Trial profile. 1201 Trial Title
  • 5. All the trials included are unique trials.

Lipid Disorders Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lipid Disorders Global Clinical Trials Review, H2, 2017" provides an overview of Lipid Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Lipid...

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World
  • Target
  • Clinical Trial profile. 240 Trial Title

Dyslipidemia Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2017" provides an overview of Dyslipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyslipidemia. Report includes an...

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • Target

Atherosclerosis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, “Atherosclerosis Global Clinical Trials Review, H1, 2017" provides an overview of Atherosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Atherosclerosis. Report...

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World
  • Target

Arteriosclerosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Arteriosclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Arteriosclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Arteriosclerosis. Report...

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World

This allows for enhanced bioavailability and EPA and DHA blood levels compared to the " esterified" fish-oil omega-## options such as LOVAZA.

  • Chronic Disease
  • Statins
  • United States
  • World
  • Product Initiative
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Omega-##-Carboxylic Acids is a complex mixture of concentrated omega-## free fatty acids purified from crude marine fish oil.

  • Endocrine Disease
  • Statins
  • United States
  • Company
  • Product Initiative
  • 8.1.1 FORECAST
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

EZETIMIBE CONTRIBUTED ##% ($##M), LEAVING ABOUT ##. ##% TO THE OMEGA-## FISH OIL DRUGS ($##M).

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 9.4.2 PERCENT DRUG-TREATED PATIENTS

Competitive Assessment MAJOR FISH OIL-DERIVED OMEGA-##S: EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA).

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.